IVSI - ETF AI Analysis
Top Page
Applied Finance IVS International Large ETF (IVSI)
Rating:67Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown positive returns so far this year and over the past month, indicating recent upward momentum.
Leading Global Companies in Top Holdings
Several of the largest positions, such as ASML and major healthcare names, have delivered strong gains, helping support the fund’s overall results.
Broad International and Sector Diversification
Holdings spread across many countries and sectors, with meaningful exposure to financials, health care, industrials, and technology, help reduce reliance on any single market or industry.
Negative Factors
Relatively High Expense Ratio
The fund’s fee is on the higher side for an ETF, which can gradually eat into investor returns over time.
Small Asset Base
With a relatively low level of assets under management, the ETF may face higher trading spreads and a greater risk of closure compared with larger funds.
Some Top Holdings Are Lagging
A few notable positions, such as LVMH and Unilever, have shown weak or negative performance this year, which can drag on the fund’s overall progress.
IVSI vs. SPDR S&P 500 ETF (SPY)
AUM7.35M
RegionDeveloped Markets
Expense Ratio0.65%
Beta1.11
IssuerApplied Finance
Inception DateDec 11, 2025
Dividend Yield0.04%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume805
30 Day Avg. Volume1,991
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
37.22Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering187
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IVSI Summary
The Applied Finance IVS International Large ETF (IVSI) is an actively managed fund that invests in large, well-established companies outside the U.S., mainly in countries like Japan, the UK, France, and Switzerland. It doesn’t track a set index, but instead picks stocks based on the manager’s research. The fund holds well-known names such as ASML, Roche, AstraZeneca, Novartis, and LVMH, and spreads money across many sectors, which can help with global diversification and long-term growth potential. A key risk is that international stocks can go up and down with global markets and currency swings.
How much will it cost me?This ETF has an expense ratio of 0.65%, which means you’ll pay about $6.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed, with managers doing in-depth research to pick international large-cap stocks rather than just tracking an index.
What would affect this ETF?This ETF could benefit if developed markets outside North America grow steadily, especially if demand stays strong for global health care, financial, and technology leaders like ASML, Roche, and AstraZeneca, and if a weaker U.S. dollar makes international stocks more attractive. On the other hand, it could face challenges from slower economic growth in Europe or Japan, tighter global financial conditions, changing regulations affecting banks and drug makers, or a downturn in commodity and luxury goods demand that would hurt holdings like Rio Tinto and LVMH.
IVSI Top 10 Holdings
IVSI leans heavily into overseas blue chips, with a clear tilt toward European health care and telecom giants. ASML has been a key engine for the fund this year, riding strong longer-term momentum even if it’s cooled recently. Drugmakers like Novartis and AstraZeneca are also pulling their weight, while Roche has been more of a question mark, losing steam in the near term. Deutsche Telekom adds a steady, income-friendly backbone, and miners like BHP and Rio Tinto give the portfolio a cyclical twist across developed markets outside North America.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 6.23% | $443.27K | €443.48B | 103.63% | 76 Outperform | |
| Roche Holding AG | 3.83% | $272.38K | $318.62B | 33.77% | 73 Outperform | |
| AstraZeneca | 3.25% | $230.88K | $314.02B | 41.71% | 80 Outperform | |
| Novartis AG | 2.95% | $209.80K | CHF224.91B | 33.87% | 80 Outperform | |
| Deutsche Telekom | 2.65% | $188.30K | €150.49B | -7.72% | 67 Neutral | |
| Tokio Marine Holdings | 1.86% | $132.10K | ¥13.79T | 40.83% | 66 Neutral | |
| Mitsubishi UFJ Financial Group | 1.82% | $129.72K | ¥30.88T | 63.32% | 76 Outperform | |
| Rio Tinto Limited | 1.75% | $124.51K | AU$230.78B | 67.05% | 78 Outperform | |
| BHP Group Ltd | 1.71% | $121.58K | AU$260.28B | 73.90% | 68 Neutral | |
| British American Tobacco | 1.67% | $118.55K | £95.48B | 42.12% | 71 Outperform |
IVSI Technical Analysis
Positive
―
Price Trends
27.02
Negative
Market Momentum
-0.23
Negative
51.78
Neutral
95.38
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IVSI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 26.16, equal to the 50-day MA of 27.02, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.23 indicates Negative momentum. The RSI at 51.78 is Neutral, neither overbought nor oversold. The STOCH value of 95.38 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IVSI.
IVSI Peer Comparison
Comparison Results
Performance Comparison
IVSI
Applied Finance IVS International Large ETF
26.60
1.26
4.97%
JIRE
JPMorgan International Research Enhanced Equity ETF
―
―
―
QUIZ
Zacks Quality International ETF
―
―
―
AIVI
WisdomTree International AI Enhanced Value Fund
―
―
―
TACN
T. Rowe Price Active Core International Equity ETF
―
―
―
PQNT
Pictet AI Enhanced International Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents